TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16540958

Group type: COMPARATOR
Intervention: Propofol by continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam by intermittent bolus administration
Number of subjects: 0
Study: 12670567

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 11052839

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2175
Study: 9175220

Group type: EXPERIMENTAL
Intervention: IABP treatment for 2 hours prior to CPB
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 33
Study: 1531823

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3927931

Group type: EXPERIMENTAL
Intervention: Nefopam (Acupan)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 90
Study: 31221280

Group type: EXPERIMENTAL
Intervention: Normal sodium diet (NS: 7 g/day of dietary sodium chloride)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low sodium diet (LS: 3 g/day of dietary sodium chloride)
Number of subjects: 44
Study: 29343128

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2-3 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: quetiapine XR 150-300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 27082942

Group type: EXPERIMENTAL
Intervention: 1-week ligation interval
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-week ligation interval
Number of subjects: 90
Study: 24586717

Group type: EXPERIMENTAL
Intervention: First dose of MR vaccine administered at 8 months and second dose of MMR vaccine administered at 18-24 months
Number of subjects: 1015
Study: 21719234

Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standing
Number of subjects: 120
Study: 20217197

Group type: EXPERIMENTAL
Intervention: Higher threat warnings from a medical source
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Higher threat warnings from a provider source
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control condition (no threat warning)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Higher threat warnings
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Depth of Information Processing
Number of subjects: 258
Study: 17686441

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to carboplatin/paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab added to cisplatin/vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib versus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib monotherapy in recurrent disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib/bevacizumab versus bevacizumab/chemotherapy versus chemotherapy alone
Number of subjects: 0
Study: 15861904

Group type: EXPERIMENTAL
Intervention: Structured Intensive Follow-Up Program (SIFUP), n=129
Number of subjects: 237

Group type: COMPARATOR
Intervention: General Cardiology Outpatient Department (COD), n=108
Number of subjects: 237
Study: 12095487

Group type: EXPERIMENTAL
Intervention: CC + recombinant FSH + recombinant LH (group A)
Number of subjects: 294

Group type: COMPARATOR
Intervention: long GnRH-a suppression + recombinant FSH (group B)
Number of subjects: 294
Study: 10484950

Group type: EXPERIMENTAL
Intervention: Melatonin 5.0 mg at bedtime
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg at bedtime
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg taken on a shifting schedule
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 8733853

Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03% solution applied every 15 minutes for 60 to 75 minutes before surgery
Number of subjects: 236

Group type: COMPARATOR
Intervention: Topical indomethacin 1% suspension applied every 15 minutes for 60 to 75 minutes before surgery
Number of subjects: 236
Study: 1808052

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 38
Study: 7075644

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nifedipine + Metoprolol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30995295

Group type: EXPERIMENTAL
Intervention: Dietary treatment with 2,850 kcal/kg and 16% CP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dietary treatment with 2,950 kcal/kg and 16.5% CP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dietary treatment with 3,050 kcal/kg and 17.0% CP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dietary treatment with 3,150 kcal/kg and 17.5% CP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lard and palm oil diets
Number of subjects: 240

Group type: COMPARATOR
Intervention: Soybean oil diet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lard diet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Addition of emulsifier
Number of subjects: 240
Study: 30515416

Group type: COMPARATOR
Intervention: Dexmedetomidine (group D) - continuous intravenous infusion of dexmedetomidine 1 μg/kg over 15 minutes before endoscopy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol (group P) - intravenously administered 2 mg/kg
Number of subjects: 88
Study: 26815196

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 59
Study: 25132426

Group type: EXPERIMENTAL
Intervention: Head Start (HS) program
Number of subjects: 2449
Study: 22492899

Group type: EXPERIMENTAL
Intervention: Preferred drug lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum allowable cost policy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint and multistate purchasing arrangements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall effect of all policies
Number of subjects: 0
Study: 19432499

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 71
Study: 18159005

Group type: EXPERIMENTAL
Intervention: TOCE+ILT
Number of subjects: 120

Group type: COMPARATOR
Intervention: TOCE+PEI
Number of subjects: 120
Study: 16185316

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bethanechol (12.5, 25 and 50 μg kg‐1 h‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12468909

Group type: EXPERIMENTAL
Intervention: Urokinase-heparin (5000 IU)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 103
Study: 9481466

Group type: EXPERIMENTAL
Intervention: Customized reminder letters
Number of subjects: 719

Group type: COMPARATOR
Intervention: Form letter
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control group (no letters)
Number of subjects: 719
Study: 7609595

Group type: EXPERIMENTAL
Intervention: [1-13C]palmitic acid
Number of subjects: 6
Study: 2228570

Group type: EXPERIMENTAL
Intervention: PALS program (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Library for free reading time (n = 25)
Number of subjects: 50
Study: 631971

Group type: EXPERIMENTAL
Intervention: Ioglicinate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Iothalamate
Number of subjects: 50
Study: 31631496

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate transparent dressing
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 474
Study: 28103073

Group type: EXPERIMENTAL
Intervention: Communities Mobilizing for Change on Alcohol (CMCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CONNECT (school-based universal screening and brief intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined condition (CMCA + CONNECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 25676588

Group type: EXPERIMENTAL
Intervention: Triptorelin (120 μg/kg body weight)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triptorelin (initial dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25614898

Group type: EXPERIMENTAL
Intervention: Earmuff
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 22091799

Group type: EXPERIMENTAL
Intervention: Blue-light LED therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham device (control)
Number of subjects: 30
Study: 19453305

Group type: EXPERIMENTAL
Intervention: REACH Risk Appraisal Measure
Number of subjects: 642
Study: 23427447

Group type: EXPERIMENTAL
Intervention: Oral fluid samples
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urine samples
Number of subjects: 125

Group type: COMPARATOR
Intervention: Serum samples
Number of subjects: 125
Study: 15232655

Group type: EXPERIMENTAL
Intervention: 123I‐BMIPP myocardial scintigraphy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Mismatch between 201Tl and 123I‐BMIPP images
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: LVEF (<45%) and number of diseased vessels (two or three)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Adding 123I‐BMIPP TDS and mismatch
Number of subjects: 159
Study: 11394955

Group type: EXPERIMENTAL
Intervention: Classroom education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 0
Study: 9316434

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 13
Study: 8281538

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 3525052

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional injection treatment (CIT)
Number of subjects: 11
Study: 28937845

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 320 mcg (80 mcg/inhalation, 4 inhalations)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 160 mcg (40 mcg/inhalation, 4 inhalations)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate MDI 320 mcg (80 mcg/inhalation, 4 inhalations)
Number of subjects: 72
Study: 27139012

Group type: EXPERIMENTAL
Intervention: FE 999049 (225 IU subcutaneous dosing)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endogenous FSH levels
Number of subjects: 24
Study: 25266159

Group type: EXPERIMENTAL
Intervention: Ivacaftor 150mg q12h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23930726

Group type: EXPERIMENTAL
Intervention: Zinc bis-glycinate 15 mg once a day for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19804808

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study: 19067260

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (n=19)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 49
Study: 12025375

Group type: EXPERIMENTAL
Intervention: gamma-radiation (n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo (n = 65)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: additional stenting
Number of subjects: 130
Study: 9755737

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Persistence of subthreshold depressive symptoms 7 months after initiation of antidepressant therapy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: History of 2 or more episodes of major depression or chronic mood symptoms for 2 years
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Patients with both risk factors
Number of subjects: 251
Study: 7661140

Group type: EXPERIMENTAL
Intervention: Electrothermal debracketing using a prototype device with a high heat tip
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (17 premolars not etched or bracketed)
Number of subjects: 48
Study: 2670580

Group type: EXPERIMENTAL
Intervention: Internal urethrotomy and TURP
Number of subjects: 200

Group type: COMPARATOR
Intervention: TURP alone
Number of subjects: 200
Study: 1276696

Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha (25 mg repeated in six hours)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Hypertonic saline (200 ml 20% NaCl)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1513
Study: 31943257

Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under am-fed conditions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under am-fastened conditions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: APT-1011 (2 3-mg orally disintegrating tablets) under hs dosing
Number of subjects: 22
Study: 30703783

Group type: EXPERIMENTAL
Intervention: B4SC anthropometric measurements
Number of subjects: 394
Study: 28576782

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 146

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 146
Study: 23336348

Group type: EXPERIMENTAL
Intervention: Recombinant tissue Plasminogen Activator (0.9 mg/kg, maximum dose 90 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion and angiography imaging
Number of subjects: 0
Study: 23806461

Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (RM)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Sham acupuncture plus RM
Number of subjects: 364

Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 364
Study: 21038962

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Flexibility-toning-balance
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 144
Study: 20117364

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Intensive clinical management
Number of subjects: 364

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Clinically managed treatment
Number of subjects: 364
Study: 17622343

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (0.2 mg/kg biweekly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (0.2 mg/kg biweekly)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both treatments (agalsidase alfa and beta)
Number of subjects: 34
Study: 15522375

Group type: EXPERIMENTAL
Intervention: Daily atropine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Weekend atropine
Number of subjects: 168
Study: 11297206

Group type: EXPERIMENTAL
Intervention: CarboMedics supraannular Top Hat valve (n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intraannular valve (n = 10)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CarboMedics supraannular Top Hat valve
Number of subjects: 17
Study: 9475315

Group type: EXPERIMENTAL
Intervention: Prenatal steroid treatment in preterm babies
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cord blood lymphocytes from preterm babies (with and without NRDS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sensitivity (ID50) of lymphocytes for dexamethasone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Functionality of glucocorticoid receptors (GR)
Number of subjects: 35
Study: 7947529

Group type: EXPERIMENTAL
Intervention: Single dose of 800 micrograms misoprostol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sequential doses of 400 micrograms misoprostol administered 2 hours apart
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Higher dose of prostaglandin (single dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sequential regimen
Number of subjects: 150
Study: 3328682

Group type: EXPERIMENTAL
Intervention: Ketanserin 0.5 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31340751

Group type: EXPERIMENTAL
Intervention: Probiotics (30 billion CFU of a mixture of six viable strains) taken orally twice daily for six months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 26903303

Group type: EXPERIMENTAL
Intervention: Powder vehicle compound of vitamin D (100,000 IU cholecalciferol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Powder vehicle compound of vitamin D
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oil vehicle compound of vitamin D (100,000 IU cholecalciferol)
Number of subjects: 15
Study: 25784512

Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg Q14 days
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Bococizumab 300 mg Q28 days
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 23300071

Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham transcutaneous posterior tibial nerve stimulation
Number of subjects: 30
Study: 21338539

Group type: EXPERIMENTAL
Intervention: Mashed potato with chicken breast, rapeseed oil, and salad
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mashed potato alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mashed potato with chicken breast and rapeseed oil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Reference food (glucose solution)
Number of subjects: 11
Study: 19685930

Group type: EXPERIMENTAL
Intervention: Perioperative combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with S-1 after D2 resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines (capecitabine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0
Study: 17267094

Group type: EXPERIMENTAL
Intervention: Cortisol 35mg orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14749694

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg for 2 days and 100 mg for 4 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study: 11514085

Group type: EXPERIMENTAL
Intervention: Two trained clinicians using a 3D camera system and pressure algometer in a double-blinded approach.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pressure algometry performed with a double-blinded approach.
Number of subjects: 20
Study: 10459508

Group type: EXPERIMENTAL
Intervention: Psychiatric diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deviance from sex role stereotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of behaviour displayed
Number of subjects: 0
Study: 7514513

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of human growth hormone (Norditropin) in the abdomen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Subcutaneous injection of human growth hormone (Norditropin) in the thigh
Number of subjects: 9
Study: 3497572

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d) and ergocalciferol (20 micrograms/d) supplementation for 6 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (69 subjects)
Number of subjects: 193
Study: 30620981

Group type: EXPERIMENTAL
Intervention: Game-based mobile rehabilitation application
Number of subjects: 2
Study: 27322571

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 24710321

Group type: EXPERIMENTAL
Intervention: Baseline plasma fatty acids profile (specifically arachidonic acid, total omega 3 polyunsaturated fatty acids, docosapentaenoic acid, docosahexaenoic acid, eicosapentaenoic acid + docosahexaenoic acid, eicosapentaenoic acid + docosapentaenoic acid + docosahexaenoic acid, stearidonic acid)
Number of subjects: 2263
Study: 23549151

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for the treatment of food allergy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early allergen exposure for primary prevention of food allergy
Number of subjects: 0
Study: 20816006

Group type: EXPERIMENTAL
Intervention: Metabolite (M)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parent drug (P)
Number of subjects: 24
Study: 18437464

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional swallowing therapy (TT)
Number of subjects: 25
Study: 16955847

Group type: EXPERIMENTAL
Intervention: Ulnar neurolysis and nerve anterior transposition with immediate range of motion (Group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ulnar neurolysis and nerve anterior transposition with immobilization (Group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ulnar neurolysis and nerve anterior transposition (both groups)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bishop scoring system (both groups)
Number of subjects: 43
Study: 14621035

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clonidine (P.O.) followed by Naltrexone (P.O.)
Number of subjects: 20